Dupixent lowers the inflammation in your lungs. It can also help some people with asthma depend less on corticosteroid medications to treat their symptoms. Some might stop needing to use steroids ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

The real game-changer? Sanofi's blockbuster drug Dupixent just posted strong Phase 2/3 trial results for treating bullous pemphigoid (BP). The drug improves disease remission and reduces severity.

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Sanofi and Regeneron’s Dupixent, which climbed one spot from ... thanks to just under $20 million spent on a trio of ads for the drug’s uses in treating depression and Alzheimer’s-associated ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...